Skip to main content
PMC home page
Annals of Oncology logoLink to Annals of Oncology
. 2019 Aug 13;30(11):1848. doi: 10.1093/annonc/mdz221

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

G V Long, K T Flaherty, D Stroyakovskiy, H Gogas, E Levchenko, F de Braud, J Larkin, C Garbe, T Jouary, A Hauschild, V Chiarion-Sileni, C Lebbe, M Mandalá, M Millward, A Arance, I Bondarenko, J B A G Haanen, J Hansson, J Utikal, V Ferraresi, P Mohr, V Probachai, D Schadendorf, P Nathan, C Robert, A Ribas, M A Davies, S R Lane, J J Legos, B Mookerjee, J -J Grob
PMCID: PMC6927319  PMID: 31406976

Ann Oncol 2017; 28(7): 1631–1639 (doi: 10.1093/annonc/mdx176)

The following funding information has been added: “This work was supported in part by The University of Texas MD Anderson Cancer Center Support Grant P30 CA016672.”

Articles from Annals of Oncology are provided here courtesy of Oxford University Press

RESOURCES